PLASMA Act

This bill modifies Medicare Part D drug discount rules for plasma-derived products - medications made from human blood or plasma, such as certain clotting factors. It establishes a specific discount percentage (based on whether beneficiaries have met their annual out-of-pocket spending limit) for these drugs instead of the standard discount. The change applies directly to Medicare Part D beneficiaries using plasma-derived medications and the manufacturers selling them under the program. It alters how discounts are calculated for these specific drugs within the Medicare Part D benefit structure.